HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

oncrasin-1

an antineoplastic agent; structure in first source

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - oncrasin-1: 6

Experts

1.	Fang, Bingliang: 3 articles (04/2011 - 09/2008)
2.	Guo, Wei: 3 articles (04/2011 - 09/2008)
3.	Wu, Shuhong: 3 articles (04/2011 - 09/2008)
4.	Liu, Jinsong: 2 articles (04/2011 - 09/2008)
5.	Liu, Xiaoying: 2 articles (04/2011 - 01/2011)
6.	Wang, Li: 2 articles (04/2011 - 01/2011)
7.	Wei, Xiaoli: 2 articles (04/2011 - 01/2011)
8.	Anh, Duong Tien: 1 article (01/2022)
9.	Bao, Le Quang: 1 article (01/2022)
10.	Dung, Do Thi Mai: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 11/09/2020 - "Oncrasin-1 is a small molecule which was identified from a screen of KRAS mutant cancer cells and has shown specificity for KRAS mutant cell killing. " 04/28/2011 - "About 40 of those compounds were as potent as or more potent than oncrasin-1 in tumor cells and had a minimal cytotoxic effect on normal cells. " 01/01/2011 - "To optimize the antitumor activity of oncrasin-1, a small molecule identified through synthetic lethality screening on isogenic K-Ras mutant tumor cells, we developed several analogues and determined their antitumor activities. " 09/15/2008 - "The in vivo administration of oncrasin-1 suppressed the growth of K-ras mutant human lung tumor xenografts by >70% and prolonged the survival of nude mice bearing these tumors, without causing detectable toxicity. " 01/01/2020 - "Based on the data from different approaches, we identified three anticancer compounds, RITA (Reactivation of p53 and Induction of Tumor cell Apoptosis), aminoflavone (AF), and oncrasin-1 (ONC-1), whose tumor cell inhibition activity is dependent on SULT1A1. "
2.	Prostatic Neoplasms (Prostate Cancer) 01/01/2022 - "A biological evaluation revealed that all thirteen compounds designed and synthesized showed strong cytotoxicity against three human cancer cell lines (SW620, colon cancer; PC-3, prostate cancer; NCI-H23, lung cancer) with eight compounds (5a, 5c-i, 5k), which were clearly more potent than both PAC-1 and oncrasin-1. "
3.	Lung Neoplasms (Lung Cancer) 01/01/2022 - "A biological evaluation revealed that all thirteen compounds designed and synthesized showed strong cytotoxicity against three human cancer cell lines (SW620, colon cancer; PC-3, prostate cancer; NCI-H23, lung cancer) with eight compounds (5a, 5c-i, 5k), which were clearly more potent than both PAC-1 and oncrasin-1. "
4.	Colonic Neoplasms (Colon Cancer) 01/01/2022 - "A biological evaluation revealed that all thirteen compounds designed and synthesized showed strong cytotoxicity against three human cancer cell lines (SW620, colon cancer; PC-3, prostate cancer; NCI-H23, lung cancer) with eight compounds (5a, 5c-i, 5k), which were clearly more potent than both PAC-1 and oncrasin-1. "

Related Drugs and Biologics

1.	RNA Polymerase II (RNA Polymerase B)
2.	Antineoplastic Agents (Antineoplastics)
3.	aminoflavone